However, in vitro anticancer activity of diosgenin against breast carcinoma, human laryngeal carcinoma, melanoma, osteosarcoma, prostate carcinoma, hepatocellular carcinoma, and human erythroleukemia have been documented due to its pleiotropic effects such as apoptosis, cell cycle arrest, inhibition of angiogenesis, invasion, and metastasis via affecting mediators involved in inflammatory cascades such as NF-kb, STAT3, AKT, and JNK (Sethi et al., 2018; Cai et al., 2020). The gene discussed is STAT3; the disease is melanoma.